openPR Logo
Press release

Radiopharmaceuticals Market Trends and Segments 2015-2025

10-19-2016 04:21 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Future Market Insights

Radiopharmaceuticals Market Trends and Segments 2015-2025

Radiopharmaceuticals are the formulations containing radioactive substances called as radioisotopes or radiotracers. Radiopharmaceuticals are intended to administer to the patient by oral route, parenteral route or IV injections or put into the body cavity; depending on the drug being administered. Small doses of radiopharmaceuticals are often used for diagnostic purpose whereas, larger doses are used for therapeutic purpose. As a therapeutic moiety, radiopharmaceuticals can either be administered to the patient per se, such as in case of metastatic prostate cancer treatment where IV injection of Radium-223 chloride is administered to the patient, or it can be given as molecular radiotherapy or radiolabelled antibody where radiotracer is attached to the cell targeting molecule. Radiopharmaceuticals are used to treat conditions such as cancers, hyperthyroidism, dementia, epilepsy etc.

Moreover, radiopharmaceuticals serve a vast applications in diagnostics including but not limited to imaging anatomy of the organ, monitoring the function of a specific organ such as heart, liver, thyroid glands, bones etc. Diagnostic radiopharmaceuticals are largely being used in techniques such as Single-photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET). According to World Nuclear Association, the number of nuclear procedures performed in U.S. in 2012 were recorded as 20 million while that in Europe was 10 million and is projected to increase by 10% by 2017. Radiopharmaceuticals when used as a diagnostic agents are called as radioactive tracers, which emit the radiations from within the body which can be continuously collected externally and monitored over a period equal to shelf life of a tracer. Some of the commercially available radiopharmaceuticals include Metastron (Strontium-89), Xofigo (Radium-223), Quadramet (samarium 153), Amyvid (Fluorine-18), ProstaScint (Indium-111), Glofil-125 (Iodine-125), Cardiogen-82 (Rubidium-82), Ceretec (Technetium-99m), Zevalin (Yttrium-90) and others.

Radiopharmaceuticals Market: Drivers and Restraints

Increasing number of nuclear procedure owing to growing prevalence of cancer, bone and heart diseases is the major driver for the growth of global radiopharmaceuticals market. According to World Nuclear Association, more than 10,000 hospitals across the world are using radioisotopes for the diagnostic purpose. Moreover, advances in nuclear imaging technology, increased usage of SPECT and PET imaging techniques, thriving demand for targeted cancer treatment are the factors fueling the growth of global market for radiopharmaceuticals over the forecast period of 2016-2026. However, side effects associated with the use of radiopharmaceuticals, stringency in regulations and high cost of a treatment are the factors hindering the growth of global radiopharmaceuticals market.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1992

Radiopharmaceuticals Market: Segmentation

The global radiopharmaceuticals market has been classified on the basis of product type, application, end user and geography.

Based on product type, the global radiopharmaceuticals market is divided into following:

Strontium-89

Radium-223

Technetium-99

Thallium-201

Iodine-125/123/131

Samarium 153

Gallium-67

Others (Phosphorus-32, Iron-59, Carbon-11 etc.)

Based on the application, the global radiopharmaceuticals market is divided into following:

Therapeutic Radiopharmaceutical/Nuclear Medicines

Cardiology

Neurology

Oncology

Endocrinology

Others (bone and joint diseases, )

Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1992

Diagnostic Radiopharmaceuticals/ Nuclear Diagnostics

Tumor/Cancer Imaging

Organ Imaging

Receptor Imaging

Radioimmunoassay

Blood Volume Measurement

Others

Based on the end user type, the global radiopharmaceuticals market is divided into following:

Hospitals

Diagnostic centers

Research institutes

Radiopharmaceuticals Market: Overview

Technetium-99 is the most widely used radiotracer in the diagnostic procedures and thus holds the maximum market share in the global radiopharmaceuticals market. According to International Atomic Energy Agency, each year more than 80% of the total nuclear diagnostic procedures performed worldwide use Technetium-99 as a radiotracer and is predicted to maintain its share over the forecast period due to abundant availability of the molybdenum-99 as a starting material. On the basis of application, diagnostic radiopharmaceuticals segment dominates the global market for radiopharmaceuticals owing to development of new and efficient techniques over the conventional diagnostic methods. In spite of comparatively less use of radiopharmaceuticals as a therapeutic agents, emergence of new effective procedures employing nuclear medicine is expected to fuel the growth of the therapeutic radiopharmaceutical application segment.

Radiopharmaceuticals Market: Regional Overview

Geographically, global radiopharmaceuticals market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan and Middle East & Africa. North America holds the largest share in the global radiopharmaceuticals market owing to advancement in healthcare infrastructure, followed by Europe. APEJ market for radiopharmaceuticals is expected to get the traction during the forecast period due to expanding adoption of hospital-based cyclotron for the commercial production of radionuclides. New indications of radiopharmaceutical agents such as FDDNP, FDOPA and novel radiotracers such as FAZA are expected to be launched in the market during the forecast period which will boost the growth of global radiopharmaceuticals market.

Speak To Analyst@ http://www.futuremarketinsights.com/askus/rep-gb-1992

Radiopharmaceuticals Market: Key Players

Some of the key players in radiopharmaceuticals market include Kimberly-Clark Corporation, Eli Lilly and Company, Lantheus Medical Imaging Inc., Ampio Pharmaceuticals Inc., GE Healthcare, Piramal Imaging, Covidien Plc., Cardinal Health, Iso Tex Diagnostics, Inc., Jubilant DraxImage Inc., Bayer HealthCare Pharmaceuticals Inc., Bracco Diagnostic Inc., Navidea Biopharmaceuticals, Nordion Inc., Spectrum Pharmaceuticals, Inc., Mallinckrodt Plc., Bio-Nucleonics Inc., IBA-Molecular, Eczac?ba??-Monrol Nuclear Products, Advanced Accelerator Applications etc.

About Us:
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.

Contact Us:
Future Market Insights
616 Corporate Way,
Suite 2-9018,
Valley Cottage,
New York 10989,
United States
Tel: +1-347-918-3531
Fax: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Radiopharmaceuticals Market Trends and Segments 2015-2025 here

News-ID: 374192 • Views:

More Releases from Future Market Insights

Global Lithium Ion Battery Separator Market Projected to Reach US$ 3,256.7 Million by 2032
Global Lithium Ion Battery Separator Market Projected to Reach US$ 3,256.7 Milli …
The lithium-ion battery separator is a critical component in lithium-ion batteries, responsible for preventing short circuits and ensuring safe and efficient battery performance. It acts as a physical barrier between the positive and negative electrodes, allowing lithium ions to pass through while blocking the flow of electrons. With advancements in separator technology, these separators play a key role in enhancing battery capacity, cycle life, and overall safety in various applications,
Industrial Drums Market on a Trajectory to Reach US$ 17.6 Billion by 2027, Bolstered by a Robust 7.1% CAGR from 2022
Industrial Drums Market on a Trajectory to Reach US$ 17.6 Billion by 2027, Bolst …
The Industrial Drums Market is experiencing a steady and promising trajectory, with an estimated value of US$ 12.5 billion in 2022, projected to escalate to US$ 17.6 billion by 2027 at a commendable Compound Annual Growth Rate (CAGR) of 7.1%. This growth is substantiated by a 6.6% CAGR in volume during 2022-27, as per Future Market Insights. Anticipated to expand 1.5 times within this period, the market presents alluring prospects for industry
Supermarkets, Convenience Stores, and Eco-friendly Choices Fuel the Expansion of the Metal Cans Industry, Catering to Health-conscious and Environmentally-aware Consumers
Supermarkets, Convenience Stores, and Eco-friendly Choices Fuel the Expansion of …
The metal cans market is predicted to grow at a CAGR of 5% over the forecast period, according to research by Future Market Insights. The industry's estimated value is expected to increase from US$ 56 Bn in 2023 to US$ 91.1 Bn by 2033. The market for metal cans has been driven by the heightened demand for the product in food and beverages industry. Metal cans helps prolong shelf-life of perishable
Folding IBCs Market Poised for Growth: Expected to Reach US$ 528 Million by 2027 with a 4.8% CAGR
Folding IBCs Market Poised for Growth: Expected to Reach US$ 528 Million by 2027 …
The folding intermediate bulk containers (IBCs) market is on a growth trajectory, with an estimated value of US$ 418 million in 2022, projected to reach US$ 528 million by 2027, showcasing a Compound Annual Growth Rate (CAGR) of 4.8%. Remarkably, the China folding IBCs market defied initial pandemic-related skepticism and is anticipated to grow by 6.9% year on year in 2022. Despite global challenges, China's folding IBCs market is poised to contribute

All 5 Releases


More Releases for Radiopharmaceuticals

Nuclear Medicine/Radiopharmaceuticals Market Growing by Convenience of Radiophar …
Nuclear Medicine/Radiopharmaceuticals Market Outlook 2022-2029 The Nuclear Medicine/Radiopharmaceuticals Market research offers complete knowledge and information on the market's flowing landscape, what is now available on the market, upcoming trends, market expectations, the competitive environment, and methods that may be used to outperform competitors. Market Analysis and Size The Nuclear Medicine/Radiopharmaceuticals Market is currently valued at US$ 10.16 Billion and is projected to register 9.90% CAGR through 2029. Gets a Sample Copy of the Nuclear
Diagnostic Radiopharmaceuticals Market 2021 | Detailed Report
According to Market Study Report, Diagnostic Radiopharmaceuticals Market provides a comprehensive analysis of the Diagnostic Radiopharmaceuticals Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. An exclusive data offered in this report is collected by research and industry experts team. Get Free Sample PDF (including full TOC, Tables and Figures) of Diagnostic Radiopharmaceuticals Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4645020 The report provides a comprehensive analysis of
Global Radiopharmaceuticals Market 2017-2021
About Radiopharmaceuticals Radiopharmaceuticals are pharmaceutical drugs having radioactive properties. The drugs can be used for therapeutic and diagnostic purposes. It is made up of radioisotope that bonds to an organic molecule. The radiopharmaceuticals find large application in the medical field due to their intrinsic properties. The radiopharmaceutical market is expected to benefit from the growing demand from the cancer market. Cancer is one of the major segments having a huge demand
Global Radiopharmaceuticals Market Global Radiopharmaceuticals Sales Report 2020
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Global Radiopharmaceutical Market Overview 1.1 Current Market Scenario 1.2 Diagnostic & Therapeutic Radiopharmaceuticals 1.3 Global Radiopharmaceticals Clinical Pipeline Overview 2. Global Radiopharmaceuticals Market Dynamics 3. Radioisotopes Used in Radiopharmaceuticals 4. EMA Guidelines for Radiopharmaceuticals 4.1 Physico-Chemical, Biological or Microbiological Tests of Medicinal Products 4.2 Toxicological & Pharmacological Tests 4.3 Clinical Documentation 4.4 Radiation
Nuclear Medicine/Radiopharmaceuticals Market
Radiopharmaceuticals are unique medicinal formulations that contain radioisotopes and are used in clinical applications for diagnosis and therapy. The facilities and procedures for production, use, and storage of radiopharmaceuticals are subject to license approval either by national or regional authorities such as Nuclear Regulatory Commission (NRC) of U.S, Atomic Energy Commission (AEC) of U.S., or Atomic Energy Regulatory Board (AERB) of India. Licensing includes compliance regarding pharmaceutical preparations and use
Global Radiopharmaceuticals Market Insight
Radioisotopes are radioactive isotopes having an unstable balance of atomic nucleus. Radioisotopes are produced either by using nuclear research reactor or by using cyclotron. These isotopes emit energy in the form of alpha, beta or gamma when changed to a stable nature. The gamma rays, thus emitted are used in Nuclear medicine, specifically in medical diagnostics. In this field, the radiation is used to provide diagnostic information about a